Therapy insight: Systemic lupus erythematosus as a risk factor for cardiovascular disease

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 8, 2005, Pages 423-430

  Haque, Sahena ^a   Bruce, Ian N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atherosclerosis; Coronary heart disease; Risk factors; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; CHOLESTEROL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANNOSE BINDING LECTIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; DIABETES MELLITUS; GENDER; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIFESTYLE; MENOPAUSE; MORBIDITY; MORTALITY; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTIPHOSPHOLIPID; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 23244462099     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0270     Document Type: Review

References (56)

1. Johnson AE et al. (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Arthritis Rheum 38: 551-557
2. McCarty DJ et al. (1995) Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 38: 1260-1270
3. Uromoto KM et al. (1999) Trends in the incidence and mortality of SLE, 1950-1992. Arthritis Rheum 42: 46-50
4. Abu-Shakra M et al. (1995) Mortality studies in SLE. Results from a single centre II: predictor variables for mortality. J Rheumatol 22: 1256-1270
5. Urowitz MB et al. (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221-225
6. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42: 338-346
7. Manzi S et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408-415
8. Hosenpud JD et al. (1984) Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 77: 286-292
9. Sella EM et al. (2003) Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 62: 1066-1070
10. Sella EM et al. (2003) Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum 48: 3168-3175
11. Roman MJ et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349: 2399-2406
12. Svenungsson E et al. (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887-1893
13. Doria A et al. (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62: 1071-1077
14. Leong KH et al. (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21: 1264-1267
15. Petri M et al. (1992) Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 71: 291-302
16. Bruce IN et al. (2003) Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 48: 3159-3167
17. Esdaile JM et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331-2337
18. Bessant R et al. (2004) Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatol 43: 924-929
19. Petri M et al. (1992) Risk factors for coronary heart disease in patients with SLE. Am J Med 93: 513-519
20. Bulkley BH and Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58: 243-264
21. Ettinger WH et al. (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83: 503-508
22. MacGregor AJ et al. (1992) Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 51: 152-155
23. Hansson GK (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352: 1685-1695
24. Spodlick DH et al. (1984) Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched controls. Am J Cardiol 53: 481-482
25. Grau AJ et al. (1995) Recent infections as a risk factor for cerebrovascular infarction. Stroke 26: 373-379
26. Wick G et al. (1995) Is atherosclerosis an immunologically mediated disease? Immunol Today 16: 27-33
27. Liuzzo G et al. (2000) Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101: 2883-2888
28. Ridker PM et al. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843
29. Boey ML et al. (1983) Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. BMJ (Clin Res Ed) 287: 1021-1023
30. Harris EN et al. (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in SLE. Lancet 2: 1211-1214
31. Ahmad Y et al. (2004) Antiphospholipid antibodies (APLA) contribute to atherogenesis in SLE. Arthritis Rheum 50 (Suppl 1): S191
32. Bilora F et al. (2002) Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin Appl Thromb Hemost 8: 103-113
33. Medina G et al. (2003) Increased carotid artery intima-media thickness may be associated with stroke in Primary Antiphospholipid Syndrome. Ann Rheum Dis 62: 607-610
34. Vaarala O et al. (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91: 23-27
35. Vaarala O et al. (1993) Cross-reaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341: 923-925
36. Witzum JL and Steinberg D (1991) Role of oxidised low-density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792
37. Hasunuma Y et al. (1997) Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107: 569-573
38. Kobayashi K et al. (2003) Circulating oxidized LDL forms complexes with beta 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44: 716-726
39. Wu R et al. (1997) Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 17: 3159-3163
40. Lahita RG et al. (1993). Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36: 1566-1574
41. Delgado AJ et al. (2003) Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatol 42: 893-899
42. Nicolo D et al. (2003) Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 48: 2974-2978
43. Nickolas TL et al. (2003) Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol 23: 406-411
44. Manger K et al. (2003) Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62: 846-850
45. Petri M et al. (1996) Plasma homocysteine as a risk factor for atherothrombotic events in SLE. Lancet 348: 1120-1124
46. Petri et al. (1992) Plasma homocysteine as a risk factor for patients with SLE. Am J Med 93: 513-519
47. Takahashi R et al. (2005) Association of mannose binding lectin and serum mannose binding lectin concentration with characteristics and progression of SLE. Ann Rheum Dis 64: 311-314
48. Ohlenschlaeger T et al. (2004) Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 351: 260-267
49. Wajed J et al. (2004) Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatol 43: 7-12
50. Sowers J (1998) Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 158: 617-621
51. Hearth-Holmes M et al. (1995) Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 22: 450-454
52. Borba EF and Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28: 780-785
53. Leung BP et al. (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170: 1524-1530
54. Wahl DG et al. (2000) Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Int Med 160: 2042-2048
55. Leung MH et al. (2002) Mortality and malignancy in the multi-ethnic Birmingham Lupus Cohort - aspirin use is beneficial and non-Caucasian origin is not associated with a poor outcome. Rheumatol 41 (Suppl 1): S17
56. Bruce IN et al. (1998). Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 16: 435-440